StreetInsider.com News Articles

VivoSim Labs adds disease models for drug efficacy testing to platform

Wed, 21 Oct 2026 08:06:15 -0400

VivoSim Labs, Inc. (Nasdaq: VIVS) announced it is expanding its NAMkind™ platform to include human disease models for efficacy testing, moving beyond its core toxicology services. The San Diego-based company made the announcement based on a press release dated Oct. 21, 2026.

The new offerings include patient-derived liver and intestinal disease models designed to help drug developers assess whether a candidate compound reduces disease markers in human tissue before clinical trials begin. VivoSim will offer efficacy testing alongside existing toxicology services on its liver and gastrointestinal models.

The platform includes two disease models. The NAMkind™ MASH model co-cultures human liver cells with

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

Wed, 21 Oct 2026 08:05:00 -0400

Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials

SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety and efficacy, today announced that it is extending its human tissue platform beyond toxicology, the core of its business today, with efficacy testing services built on NAMkind™ disease models of the liver and intestine. The disease models are built with

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

Wed, 21 Oct 2026 08:05:00 -0400

Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials

Form 8-K VivoSim Labs, INC. For: Oct 13

Fri, 16 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261016/27197972.html

FDA updates drug testing rules, opening path for non-animal methods

Wed, 07 Oct 2026 08:05:45 -0400

VivoSim Labs, Inc. (Nasdaq: VIVS) issued a statement welcoming a U.S. Food and Drug Administration direct final rule that updates federal regulations to allow non-animal testing methods for evaluating the safety of drugs and biological products intended for human use.

The FDA's rule replaces the term "animal tests" with "nonclinical tests" across its regulatory framework, formally creating pathways for New Approach Methodologies (NAMs), including human cell-based testing models.

VivoSim, based in San Diego, develops three-dimensional human tissue models of liver and intestine used in preclinical drug safety testing. The company says its liver tissue models can identify drug candidates likely to cause

FDA updates drug testing rules, opening path for non-animal methods

Wed, 07 Oct 2026 08:05:45 -0400

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

Wed, 07 Oct 2026 08:05:00 -0400

As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs

SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today celebrated the U.S. Food and Drug Administration's (FDA) direct final rule updating its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products intended for human use.

The FDA’s new rule replaces the term

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

Wed, 07 Oct 2026 08:05:00 -0400

As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs

The FDA’s new rule replaces the term

Form 8-K VivoSim Labs, INC. For: Sep 30

Tue, 06 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261006/27155462.html

VivoSim Labs presents drug toxicity data at EUROTOX 2026

Wed, 16 Sep 2026 08:05:43 -0400

VivoSim Labs, Inc. (NASDAQ: VIVS) presented new data from its NAMkind™ 3D human tissue platforms at the 58th Congress of the European Societies of Toxicology (EUROTOX 2026) in Vienna, Austria, on Sept. 16, 2026, showing the platforms' ability to predict liver and gastrointestinal drug toxicity across small molecules and Antibody-Drug Conjugates (ADCs).

The company's NAMkind™ Liver platform supports liver spheroid viability for up to 28 days, while its intestinal models maintain barrier integrity for up to three weeks. According to the press release, this extended culture duration allows researchers to evaluate repeat-dose effects that shorter laboratory assays may not capture.

In studies

VivoSim Labs presents drug toxicity data at EUROTOX 2026

Wed, 16 Sep 2026 08:05:43 -0400

In studies

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

Wed, 16 Sep 2026 08:05:00 -0400

New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities

SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ: VIVS) (“VivoSim” or the “Company”) unveils new clinical benchmark data at the 58th Congress of the European Societies of Toxicology (EUROTOX 2026) in Vienna, Austria, demonstrating the ability of its NAMkind™ 3D human liver and intestinal platforms to predict drug toxicity across small molecules and increasingly complex therapies, including Antibody-Drug Conjugates (ADCs).

The new data strengthens VivoSim's positioning in the growing

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

Wed, 16 Sep 2026 08:05:00 -0400

New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities

The new data strengthens VivoSim's positioning in the growing

VivoSim Labs plans rat liver model to pair with human platform

Tue, 01 Sep 2026 08:06:07 -0400

VivoSim Labs, Inc. (Nasdaq: VIVS) announced plans to develop a rat liver model that would complement its existing NAMkind human liver platform, according to a press release from the San Diego-based company.

The planned model is intended to help pharmaceutical companies determine when liver toxicity observed in rats may be species-specific and not relevant to humans. VivoSim's current human liver model is designed to identify human toxicity that may not appear in animal studies, while the rat model would provide the reverse capability.

"This gives us the ability to look at the same toxicity question from both sides," said Keith Murphy, Executive

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

Tue, 01 Sep 2026 08:05:00 -0400

New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to develop a rat liver model that will complement its existing NAMkind™ human liver platform and expand the Company’s liver toxicology capabilities.

The new model is designed to address a longstanding challenge in drug development: toxicity observed in rats does not always

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

Tue, 01 Sep 2026 08:05:00 -0400

New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans

The new model is designed to address a longstanding challenge in drug development: toxicity observed in rats does not always

Form ARS VivoSim Labs, INC. For: Mar 31

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961400.html

Form ARS VivoSim Labs, INC. For: Mar 31

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961400.html

Form 8-K VivoSim Labs, INC. For: Aug 17

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961380.html

Form 8-K VivoSim Labs, INC. For: Aug 17

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961380.html

Form DEF 14A VivoSim Labs, INC. For: Sep 30

Fri, 21 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260821/26961302.html

Form DEF 14A VivoSim Labs, INC. For: Sep 30

Fri, 21 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260821/26961302.html

Form SCHEDULE 13G/A VivoSim Labs, INC. Filed by: Esousa Group Holdings LLC

Mon, 17 Aug 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260817/26939365.html

Form SCHEDULE 13G/A VivoSim Labs, INC. Filed by: Esousa Group Holdings LLC

Mon, 17 Aug 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260817/26939365.html

Form PRER14A VivoSim Labs, INC.

Thu, 13 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260813/26922529.html